IMODIUM MULTI-SYMPTOM RELIEF
LOE Approachingloperamide hydrochloride and dimethicone
NDAORALTABLET
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMODIUM MULTI-SYMPTOM RELIEF is an oral tablet combining loperamide hydrochloride (an antidiarrheal agent) and dimethicone (an anti-gas agent) approved in 2000. It treats acute diarrhea with concurrent gas and bloating symptoms by reducing intestinal motility while alleviating gastrointestinal distension. The combination addresses multiple GI complaints in a single OTC formulation.
LOE Approaching
As a 24-year-old product approaching loss of exclusivity with moderate competitive pressure (30), brand team size and investment are likely shrinking.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature LOE-approaching lifecycle; career growth is limited. Roles on this product typically involve brand defense, retailer relations, and cost management rather than launches or innovation.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.